Search

Your search keyword '"Barbara L. Parsons"' showing total 88 results

Search Constraints

Start Over You searched for: Author "Barbara L. Parsons" Remove constraint Author: "Barbara L. Parsons"
88 results on '"Barbara L. Parsons"'

Search Results

1. A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

2. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

3. Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids

4. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas

5. Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing

6. Quantification of cancer driver mutations in human breast and lung <scp>DNA</scp> using targeted, error‐corrected <scp>CarcSeq</scp>

7. Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk

8. A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

9. CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia

11. ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations

12. ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations

13. Modern conception of carcinogenesis creates opportunities to advance cancer risk assessment

14. LifespanKrasmutation levels in lung and liver of B6C3F1mice

16. Variation in organ-specificPIK3CAandKRASmutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas

17. Dose and temporal evaluation of ethylene oxide-induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations

18. Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology

19. Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids

20. Multiclonal tumor origin: Evidence and implications

21. Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation

22. Lifespan Kras mutation levels in lung and liver of B6C3F

23. Ovarian effects of prenatal exposure to benzo[a]pyrene: Roles of embryonic and maternal glutathione status

24. Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas

25. Temporal Changes in K-ras Mutant Fraction in Lung Tissue of Big Blue B6C3F1 Mice Exposed to Ethylene Oxide

26. ACB-PCR measurement of spontaneous and furan-induced H-rasCodon 61 CAA to CTA and CAA to AAA mutation in B6C3F1 mouse liver

27. Dose and temporal evaluation of ethylene oxide-induced mutagenicity in the lungs of male big blue mice following inhalation exposure to carcinogenic concentrations

28. A subset of papillary thyroid carcinomas containKRASmutant subpopulations at levels above normal thyroid

29. ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues

30. p53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene

31. Oncomutations as biomarkers of cancer risk

32. K-RAS mutation in the screening, prognosis and treatment of cancer

33. Many different tumor types have polyclonal tumor origin: Evidence and implications

34. Simulated solar light‐inducedp53mutagenesis in SKH‐1 mouse skin: A dose–response assessment

35. Low-frequency KRAS mutations are prevalent in lung adenocarcinomas

36. ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue(R) rats treated with N-hydroxy-2-acetylaminofluorene

37. Frequency and types of spontaneous Hprt lymphocyte mutations in Pms2-deficient mice

38. Levels of H-ras codon 61 CAA to AAA mutation: response to 4-ABP-treatment and Pms2-deficiency

39. 4-Aminobiphenyl induces liver DNA adducts in both neonatal and adult mice but induces liver mutations only in neonatal mice

40. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development

41. Quantifying levels ofp53 mutation in mouse skin tumors

42. Pms2 deficiency results in increased mutation in the Hprt gene but not the Tk gene of Tk+/- transgenic mice

43. Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression

44. ACB-PCR quantification of somatic oncomutation

45. ACB-PCR Quantification of Somatic Oncomutation

46. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment

47. Detection of basepair substitution mutation at a frequency of 1 × 10−7 by combining two genotypic selection methods, MutEx enrichment and allele-specific competitive blocker PCR

48. Evaluation of MutS as a tool for direct measurement of point mutations in genomic DNA

49. Temporal changes in K-ras mutant fraction in lung tissue of big blue B6C3F₁ mice exposed to ethylene oxide

50. Personalized cancer treatment and the myth of KRAS wild-type colon tumors

Catalog

Books, media, physical & digital resources